Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell acute lymphoblastic leukemia

Leukemia

Volumn 23, Issue 3, 2009, Pages 627-629

  Deenik, W ^a   Beverloo, H B ^a   van der Poel van de Luytgaarde, S C P A M ^a   Wattel, M M ^a   van Esser, J W J ^b   Valk, P J M ^a   Cornelissen, J J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b AMPHIA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; BCR ABL PROTEIN; CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; DAUNORUBICIN; IMATINIB; METHOTREXATE; MITOXANTRONE; NUP214 PROTEIN; PREDNISONE; PROTEIN TYROSINE KINASE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG; VINCRISTINE;

ABSENCE OF SIDE EFFECTS; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; CANCER REGRESSION; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; ERYTHROCYTE TRANSFUSION; FEBRILE NEUTROPENIA; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE AMPLIFICATION; HUMAN; LYMPHOCYTIC INFILTRATION; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; T CELL LEUKEMIA; T LYMPHOBLAST; THROMBOCYTE TRANSFUSION;

EID: 62649090105     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.318     Document Type: Article

References (8)

1. Barber KE, Martineau M, Harewood L, Stewart M, Cameron E, Strefford JC et al. Amplification of the ABL gene in T-cell acute lymphoblastic leukemia. Leukemia 2004; 18: 1153-1156.
2. Graux C, Cools J, Melotte C, Quentmeier H, Ferrando A, Levine R et al Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet 2004; 36: 1084-1089.
3. Burmeister T, Gökbuget N, Reinhardt R, Rieder H, Hoelzer D, Schwartz S. NUP214-ABL1 in adult T-ALL: The GMALL study group experience. Blood 2006; 108: 3556-3559.
4. Stergianou K, Fox C, Russell NH. Fusion of NUP214 to ABL1 on amplified episomes in T-ALL - implications for treatment. Leukemia 2005; 19: 1680-1681.
5. De Keersmaecker K, Versele M, Cools J, Superti-Furga G, Hantschel O. Intrinsic differences between the catalytic properties of the oncogenic NUP214-ABL1 and BCR-ABL1 fusion protein kinases. Leukemia 2008, e-pub ahead of print.
6. De Keersmaecker K, Porcu M, Gielen O, Cools J. LCK is a critical signaling effector in NUP214-ABL1 positive T-ALL. Haematologica 2008; 93 (s1) (abstract (0476)).
7. Quintas-Cardama A, Tang W, Manshouri T, Vega F, Lennon PA, Cools J et al. Activity of tyrosine kinase inhibitors against NUP214-ABL1-positive T cell malignancies. Leukemia 2008; 22: 1117-1124.
8. Goldstone AH, Richards SM, Lazarus HM, Tahirhan MS, Buck G, Fielding AK et al. In adults with standard-risk acute lymphoblastic leukemia the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/ maintenance chemotherapy in all patients: Final results of the international ALL Trial (MRC UKALL XII/ECOG E2993). Blood 2008; 111: 1827-1833.